Evidence map›Paper›PMID 34628543›Full record

ArticleInternational ophthalmology2022

Clinical variations and therapeutic challenges in the management of symptomatic retinal artery macroaneurysm: a tertiary center experience.

Deepak Khadka, Konstantinos T Tsaousis, Arjun Shrestha, Barsha Suwal, Nirsara Shrestha, Samata Sharma, Rinkal Suwal, Bijay Khatri

Abstract read
PubMed Publisher
In one paragraph

Article in International ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Deepak KhadkaDepartment of Ophthalmology, BP Eye Foundation, Hospital for Children, Eye, ENT, and Rehabilitation Services, Lokanthali, Madhyapur Thimi, Bhaktapur, Bagmati, Nepal. drdeepak123@hotmail.com.ORCID http://orcid.org/0000-0001-8436-129X
Konstantinos T TsaousisDepartment of Ophthalmology, Leicester Royal Infirmary, University Hospitals of Leicester, Leicester, UK.
Arjun ShresthaDepartment of Ophthalmology, BP Eye Foundation, Hospital for Children, Eye, ENT, and Rehabilitation Services, Lokanthali, Madhyapur Thimi, Bhaktapur, Bagmati, Nepal.
Barsha SuwalDepartment of Ophthalmology, BP Eye Foundation, Hospital for Children, Eye, ENT, and Rehabilitation Services, Lokanthali, Madhyapur Thimi, Bhaktapur, Bagmati, Nepal.
Nirsara ShresthaDepartment of Ophthalmology, BP Eye Foundation, Hospital for Children, Eye, ENT, and Rehabilitation Services, Lokanthali, Madhyapur Thimi, Bhaktapur, Bagmati, Nepal.
Samata SharmaDepartment of Ophthalmology, BP Eye Foundation, Hospital for Children, Eye, ENT, and Rehabilitation Services, Lokanthali, Madhyapur Thimi, Bhaktapur, Bagmati, Nepal.
Rinkal SuwalDepartment of Optometry, BP Eye Foundation, Hospital for Children, Eye, ENT, and Rehabilitation Services, Lokanthali, Madhyapur Thimi, Bhaktapur, Bagmati, Nepal.
Bijay KhatriAcademic and Research Department, BP Eye Foundation, Hospital for Children, Eye, ENT, and Rehabilitation Services, Lokanthali, Madhyapur Thimi, Bhaktapur, Bagmati, Nepal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo find out clinical characteristics, therapeutic options, and visual outcome in symptomatic retinal artery macroaneurysm (RAMA) patients.

methodNewly diagnosed cases of symptomatic RAMA from January 2015 to December 2019 were included. Fifteen eyes of 15 patients with mean age 62.46 years ± 14.89 (SD) fulfilled the inclusion criteria.

resultHypertension was present in 66.6% of the patients, and the commonest site was superotemporal (12 eyes, 80%). The most commonly employed treatment was Nd: Yag laser hyaloidotomy in 4 eyes (26.6%). Other treatments were intravitreal bevacizumab in 3 eyes (20%), focal laser with intravitreal bevacizumab in 3 eyes (20%), PPV with focal laser (13.3%) in 2, focal laser only in one (6.6%), PPV with focal and intravitreal bevacizumab in one (6.6%). The mean best-corrected visual acuity (BCVA) at baseline was 1.35 ± 0.84 LogMAR, which improved to 0.39 ± 0.53 LogMAR at the last follow-up. Presenting VA 0.77 (±0.40) improved to 0.20 (±0.17) p value (0.180) in intravitreal bevacizumab only group, 1.29 (±0.35) to 0.75 (±0.15) p value 0.66 in Nd: Yag laser group, 2.67 (±0.58) to 0.46 (±0.28) p value 0.019 in PPV group and did not improve in combined anti-VEGF and focal laser group due to dense hard exudates at the fovea in one and persistent cystoid macular edema in another case.

conclusionWith regard to its presentation, which can vary tremendously, there are no approved guidelines for its treatment. The present study reinforces the need for a treatment guideline development. Customization of treatment should be considered depending on the clinical presentation of each case.

Indexed as

AneurysmRetinal ArteryAngiogenesis InhibitorsBevacizumabHumansIntravitreal InjectionsMiddle AgedRanibizumabTreatment OutcomeVascular Endothelial Growth Factor AVisual AcuityAngiogenesis InhibitorsBevacizumabRanibizumabVascular Endothelial Growth Factor AAnti-vascular endothelial growth factorFocal laserHypertensionIntravitreal bevacizumabNd: Yag laser hyaloidotomyPPVSuperotemporal

Identifiers

PMID34628543

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.